BPX-601 is under clinical development by Bellicum Pharmaceuticals and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BPX-601’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BPX-601 overview

BPX-601 is under development for the treatment of solid tumors including prostate cancer, gastro esophageal junction carcinoma, metastatic gastric cancer and hormone-refractory prostate cancer. It is administered through intravenous (infusion) route. The therapy is composed of retroviral vector transduced CAR T cells that target prostate stem cell antigen (PSCA) and rimiducid. The drug candidate is based on the GoCAR-T technology. The technology includes proprietary inducible MyD88/CD40 (iMC) activation switch, to enable control of the activation and proliferation of the T cells through the scheduled administration of a course of rimiducid infusions. It was also under development for the treatment of leukemia and metastatic pancreatic cancer.

Bellicum Pharmaceuticals overview

Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, that develops cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the areas of cellular immunotherapy including hematopoietic stem cell transplantation, CAR T cell therapy and TCR cell therapies. Bellicum’s lead pipeline candidate includes BPX-501, an adjunct T cell therapy intended for the treatment of leukemias, lymphomas and genetic blood diseases. The company also develops pipeline products for the treatment of solid tumors, hematological cancers and others. Bellicum is headquartered in Houston, Texas, the US.

For a complete picture of BPX-601’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.